Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diffusion Magnetic Resonance Imaging | 3 | 2017 | 7 | 1.160 |
Why?
|
| Lymphedema | 2 | 2016 | 3 | 0.950 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 4 | 0.950 |
Why?
|
| Stomach Neoplasms | 2 | 2017 | 5 | 0.630 |
Why?
|
| Female | 16 | 2017 | 971 | 0.600 |
Why?
|
| Humans | 18 | 2017 | 1892 | 0.580 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 3 | 0.540 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1 | 0.530 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 3 | 0.530 |
Why?
|
| Male | 14 | 2017 | 1041 | 0.470 |
Why?
|
| Middle Aged | 12 | 2017 | 488 | 0.370 |
Why?
|
| Aged | 10 | 2017 | 414 | 0.330 |
Why?
|
| Adult | 8 | 2016 | 551 | 0.280 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2017 | 6 | 0.270 |
Why?
|
| Contrast Media | 3 | 2016 | 9 | 0.260 |
Why?
|
| Alzheimer Disease | 2 | 2017 | 80 | 0.260 |
Why?
|
| Rhinitis | 2 | 2016 | 2 | 0.240 |
Why?
|
| Sinusitis | 2 | 2016 | 2 | 0.240 |
Why?
|
| Asthma | 2 | 2016 | 7 | 0.230 |
Why?
|
| Treatment Outcome | 5 | 2017 | 118 | 0.230 |
Why?
|
| Coronary Vessels | 2 | 2015 | 2 | 0.220 |
Why?
|
| Coronary Thrombosis | 3 | 2015 | 3 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 59 | 0.220 |
Why?
|
| Coronary Angiography | 5 | 2015 | 7 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 69 | 0.200 |
Why?
|
| Child, Preschool | 3 | 2017 | 87 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2015 | 6 | 0.190 |
Why?
|
| Child | 3 | 2017 | 156 | 0.190 |
Why?
|
| Adolescent | 3 | 2017 | 187 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 60 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2017 | 18 | 0.160 |
Why?
|
| Infant | 2 | 2017 | 89 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2017 | 102 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 48 | 0.160 |
Why?
|
| Fibrosis | 2 | 2016 | 4 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 98 | 0.140 |
Why?
|
| Drug-Eluting Stents | 2 | 2015 | 2 | 0.140 |
Why?
|
| Vascular Diseases | 1 | 2017 | 3 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 2 | 0.140 |
Why?
|
| Leucovorin | 1 | 2017 | 1 | 0.130 |
Why?
|
| Fluorouracil | 1 | 2017 | 1 | 0.130 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2017 | 1 | 0.130 |
Why?
|
| Mice, Nude | 1 | 2017 | 3 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 4 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2017 | 5 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 12 | 0.130 |
Why?
|
| Random Allocation | 1 | 2017 | 12 | 0.130 |
Why?
|
| Brain Ischemia | 1 | 2017 | 14 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 1 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 2 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 2 | 0.130 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 1 | 0.130 |
Why?
|
| Animals | 2 | 2017 | 735 | 0.130 |
Why?
|
| Adenoviridae | 1 | 2016 | 1 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 8 | 0.130 |
Why?
|
| Aging | 1 | 2017 | 75 | 0.130 |
Why?
|
| Mice | 1 | 2017 | 209 | 0.120 |
Why?
|
| Observer Variation | 1 | 2016 | 8 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 29 | 0.120 |
Why?
|
| Nasal Polyps | 1 | 2016 | 1 | 0.120 |
Why?
|
| Rhinoplasty | 1 | 2016 | 1 | 0.120 |
Why?
|
| Turbinates | 1 | 2016 | 1 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2016 | 11 | 0.120 |
Why?
|
| Absorbable Implants | 1 | 2015 | 1 | 0.110 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2015 | 1 | 0.110 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 2 | 0.110 |
Why?
|
| Cardiovascular Agents | 1 | 2015 | 2 | 0.110 |
Why?
|
| Polymers | 1 | 2015 | 5 | 0.110 |
Why?
|
| Sirolimus | 1 | 2015 | 3 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2016 | 119 | 0.110 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2014 | 1 | 0.110 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 1 | 0.110 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2014 | 1 | 0.110 |
Why?
|
| Adenosine | 1 | 2014 | 2 | 0.110 |
Why?
|
| Nitroprusside | 1 | 2014 | 4 | 0.110 |
Why?
|
| Angiography | 1 | 2013 | 1 | 0.100 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 1 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2013 | 1 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 3 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2013 | 9 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 4 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 17 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2012 | 5 | 0.100 |
Why?
|
| Stents | 1 | 2012 | 6 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 5 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 209 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2017 | 43 | 0.080 |
Why?
|
| Chemokines, CXC | 1 | 2009 | 1 | 0.080 |
Why?
|
| Receptors, Scavenger | 1 | 2009 | 1 | 0.080 |
Why?
|
| Introns | 1 | 2009 | 5 | 0.080 |
Why?
|
| Time Factors | 3 | 2015 | 143 | 0.080 |
Why?
|
| Hepatic Artery | 1 | 2005 | 1 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 36 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 4 | 0.060 |
Why?
|
| Oxygen | 1 | 2005 | 8 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2016 | 15 | 0.060 |
Why?
|
| ROC Curve | 2 | 2016 | 12 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 69 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 59 | 0.050 |
Why?
|
| Risk Factors | 2 | 2015 | 140 | 0.050 |
Why?
|
| Apathy | 1 | 2017 | 1 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 2017 | 2 | 0.030 |
Why?
|
| Anisotropy | 1 | 2017 | 8 | 0.030 |
Why?
|
| Ischemia | 1 | 2017 | 2 | 0.030 |
Why?
|
| White Matter | 1 | 2017 | 6 | 0.030 |
Why?
|
| Dementia | 1 | 2017 | 31 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 28 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 107 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 6 | 0.030 |
Why?
|
| Gadolinium | 1 | 2016 | 1 | 0.030 |
Why?
|
| Meglumine | 1 | 2016 | 1 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 1 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2016 | 2 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2016 | 5 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 5 | 0.030 |
Why?
|
| Cognition | 1 | 2017 | 73 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 4 | 0.030 |
Why?
|
| Brain | 1 | 2017 | 92 | 0.030 |
Why?
|
| Myocardium | 1 | 2016 | 46 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 55 | 0.030 |
Why?
|
| Gestational Age | 1 | 2016 | 8 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 8 | 0.030 |
Why?
|
| Pregnancy | 1 | 2016 | 44 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 2 | 0.030 |
Why?
|
| Endoscopy | 1 | 2016 | 3 | 0.030 |
Why?
|
| Smell | 1 | 2016 | 6 | 0.030 |
Why?
|
| Young Adult | 1 | 2016 | 142 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2016 | 107 | 0.030 |
Why?
|
| Coronary Restenosis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Neointima | 1 | 2015 | 1 | 0.030 |
Why?
|
| Chromium Alloys | 1 | 2015 | 4 | 0.030 |
Why?
|
| China | 1 | 2015 | 6 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2015 | 21 | 0.030 |
Why?
|
| Bronchial Provocation Tests | 1 | 2014 | 1 | 0.030 |
Why?
|
| Paranasal Sinuses | 1 | 2014 | 2 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 10 | 0.030 |
Why?
|
| Flushing | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hyperemia | 1 | 2014 | 1 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 3 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2014 | 4 | 0.030 |
Why?
|
| Headache | 1 | 2014 | 7 | 0.030 |
Why?
|
| Dyspnea | 1 | 2014 | 7 | 0.030 |
Why?
|
| Incidence | 1 | 2014 | 45 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 1 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 7 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 60 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 2 | 0.020 |
Why?
|
| Platelet Function Tests | 1 | 2012 | 1 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 13 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 28 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2012 | 1 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 2 | 0.020 |
Why?
|
| Heparin | 1 | 2012 | 4 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 27 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 7 | 0.020 |
Why?
|
| Chemokine CXCL16 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 9 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 8 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 13 | 0.020 |
Why?
|
| Lipids | 1 | 2009 | 9 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 37 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 19 | 0.020 |
Why?
|
| Liver Circulation | 1 | 2005 | 1 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2005 | 2 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2005 | 3 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 3 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2005 | 11 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 4 | 0.020 |
Why?
|
| Rabbits | 1 | 2005 | 52 | 0.010 |
Why?
|